COMP <GO>
TVTX vs ABBV // OPERATING MARGIN
Travere Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TVTX 4
— ABBV 9
▲ OPERATING MARGIN LEADER: ABBV
LAST: $50.39 (-0.36%) • MKT CAP: $4.77B
operating-margins
-12.80%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
operating-margins
24.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVTX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TVTX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | TVTX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -13.00% | 29.00% | -42.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.33% | 3.47% | -3.14 | ABBV | /fcf-yield <GO> |
| Operating Margin ACTIVE | -12.80% | 24.60% | -37.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -5.20% | 6.90% | -12.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 110.50% | 8.60% | +101.90 | TVTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.44 | 5.33 | -1.89 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.40% | -0.20 | TVTX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.4 | 72.8 | -37.34 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.0x | 113.1x | -95.10 | TVTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $513.86B | -$509.09B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TVTX REV | ABBV REV | TVTX GROSS % | ABBV GROSS % | TVTX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $490.7M | $61.16B | 97.9% | 70.2% | $15.7M | $17.82B |
| FY 2024 | $233.2M | $56.33B | 96.7% | 70.0% | -$248.0M | $17.83B |
| FY 2023 | $145.2M | $54.32B | 44.0% | 44.0% | -$286.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVTX // BETA 1.08
ABBV // BETA 1.15